Why the study?
Cisplatin is widely used in adults and children, but causes toxicities that may be reduced by the potential chemoprotectant N-acetylcysteine.
Does N-acetylcysteine reduce cisplatin toxicity in adults and children receiving cisplatin treatment?
Does N-acetylcysteine reduce cisplatin toxicity in adults and children receiving cisplatin treatment?
N-acetylcysteine represents a potential chemoprotective agent to decrease toxicities secondary to cisplatin treatment without compromising its antitumor efficacy.
Answers are grounded in this paper and cite their sources.
Late NAC may reduce cisplatin toxicities without compromising efficacy; leaves open clinical translation.
N-acetylcysteine (NAC) is a membrane-permeable cysteine precursor capable of enhancing the intracellular cysteine pool, enhancing cellular glutathione (GSH) synthesis, and thus potentiating the endogenous antioxidant mechanism. Late administration of NAC after cisplatin has been shown in different in vivo studies to reduce the side effects caused by various toxicities at different levels without affecting the antitumor efficacy of platinum, improving total and enzymatic antioxidant capacity and decreasing oxidative stress markers. These characteristics provide NAC with a rationale as a potentially effective chemo protectant in cisplatin-based therapeutic cycles. NAC represents a potential candidate as a chemoprotective agent to decrease toxicities secondary to cisplatin treatment. It suggests that it could be used in clinical trials, whereby the effective dose, timing, and route should be adjusted to optimize chemoprotection. This review provides an overview of the effect of NAC on cisplatin toxicity, a drug widely used in the clinic in adults and children.
No takes yet. Share an insight, caveat, or question.
Zavala-Valencia et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: